Literature DB >> 8723744

Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19.

L C Wienkers1, C J Wurden, E Storch, K L Kunze, A E Rettie, W F Trager.   

Abstract

Kinetic studies demonstrate that two forms of human liver cytochrome P450 are responsible for the formation of (R)-8-hydroxywarfarin: a low-affinity enzyme (KM approximately 1.5 mM), previously identified as P4501A2; and a high-affinity enzyme (KM = 330 microM), now identified as P4502C19 on the basis of the following evidence. In crossover inhibition studies with P4501A2-depleted human liver microsomes between (R)-warfarin and (S)-mephenytoin, reciprocal competitive inhibition was observed. Apparent KM values for (S)-mephenytoin-4'-hydroxylation (52-67 microM) were similar to the determined Ki values (58-62 microM) for (S)-mephenytoin inhibition of (R)-8-hydroxywarfarin formation. Similarly, the apparent KM for (R)-warfarin 8-hydroxylation in furafylline-pretreated microsomes (KM = 289-395 microM) was comparable with the Ki values (280-360 microM) for (R)-warfarin inhibition of (S)-4'-hydroxymephenytoin formation. Inhibition studies with tranylcypromine, a known inhibitor of (S)-mephenytoin hydroxylase activity, and either substrate in three different microsomal preparations yielded nearly identical inhibitory constants: Ki = 8.7 +/- 1.6 microM for inhibition of (S)-4'-hydroxymephenytoin formation and 8.8 +/- 2.5 microM for inhibition of (R)-8-hydroxywarfarin formation. In addition, fluconazole, a potent inhibitor of (R)-warfarin 8-hydroxylation, Ki = 2 microM, was found to inhibit (S)-mephenytoin hydroxylation with an identical Ki (2 microM). Finally, a strong correlation between (S)-mephenytoin 4-hydroxylation and (R)-warfarin 8-hydroxylation activities in furafylline-pretreated microsomes was demonstrated in 14 human liver microsomal preparations (r2 = 0.97).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8723744

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  27 in total

Review 1.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

2.  Voriconazole and fluconazole increase the exposure to oral diazepam.

Authors:  Teijo I Saari; Kari Laine; Leif Bertilsson; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2007-08-04       Impact factor: 2.953

Review 3.  Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.

Authors:  Mike Ufer
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel.

Authors:  Tuomas Korhonen; Ari Tolonen; Jouko Uusitalo; Stefan Lundgren; Jorma Jalonen; Kari Laine
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

5.  Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen.

Authors:  Ville-Veikko Hynninen; Klaus T Olkkola; Kari Leino; Stefan Lundgren; Pertti J Neuvonen; Anders Rane; Mika Valtonen; Hanna Vyyryläinen; Kari Laine
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

6.  Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.

Authors:  Mikko Niemi; Janne T Backman; Laura Juntti-Patinen; Mikko Neuvonen; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

Review 7.  Development and Uses of Offline and Web-Searchable Metabolism Databases - The Case of Benzo[a]pyrene.

Authors:  Slobodan P Rendic; Frederick P Guengerich
Journal:  Curr Drug Metab       Date:  2018       Impact factor: 3.731

8.  Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl.

Authors:  Teijo I Saari; Kari Laine; Mikko Neuvonen; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2007-11-07       Impact factor: 2.953

Review 9.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 10.  Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?

Authors:  Mohamed H A Shahin; Julie A Johnson
Journal:  Curr Opin Cardiol       Date:  2013-05       Impact factor: 2.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.